Search criteria | ||||
The cost-effectiveness of physical activity in the management of COPD patients in the UK | ||||
Ramos M1, Lamotte M1, Gerlier L1, Svangren P2, Miquel-Cases A3, Haughney J4 | ||||
1 IQVIA, Zaventem, Belgium 2 Core Respiratory, Global Product and Portfolio Strategy - Global Payer Evidence and Pricing, AstraZeneca Gothenburg R&D, Mölndal, Sweden 3 Global Price and Reimbursement, Global Payer Evidence and Pricing, AstraZeneca Gothenburg R&D, Cambridge, UK 4 Academic Primary Care Division of Applied Health Sciences, University of Aberdeen, Aberdeen, UK. | ||||
Int J Chron Obstruct Pulmon Dis. 2019 Jan 15;14:227-239 |
||||
, Article | ||||
, Scotland | ||||
Abstract: doi: 10.2147/COPD.S181194. eCollection 2019 | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Respiratory disease | 2019 | English | , Cost effectiveness | |